Marty Stanton

Title: Marty Stanton: Innovator in Lung Cancer Detection

Introduction

Marty Stanton is a notable inventor based in Boulder, Colorado, recognized for his contributions to the field of lung cancer diagnostics. With a total of two patents to his name, Stanton has made significant strides in developing innovative methods for the detection and diagnosis of lung cancer.

Latest Patents

Stanton's latest patents include groundbreaking work on lung cancer biomarkers and multiplexed analyses of test samples. The first patent focuses on biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. This application provides biomarkers that can be utilized alone or in various combinations to diagnose lung cancer or differentiate between benign and malignant pulmonary nodules. The second patent describes methods and devices for detecting one or more target molecules in a test sample, particularly emphasizing the detection and quantification of non-nucleic acid targets, such as proteins, using nucleic acid technologies.

Career Highlights

Marty Stanton is currently employed at Somalogic, Incorporated, where he continues to advance his research in biomarker development and cancer diagnostics. His work has the potential to significantly impact the early detection of lung cancer, improving patient outcomes through timely diagnosis.

Collaborations

Stanton collaborates with esteemed colleagues, including Dominic Zichi and Larry M Gold, who contribute to his research endeavors and the development of innovative diagnostic solutions.

Conclusion

Marty Stanton's work in lung cancer detection exemplifies the importance of innovation in medical diagnostics. His patents and ongoing research at Somalogic, Incorporated, highlight his commitment to improving healthcare through technology.